What do we know about it?
Gene editing is a revolutionary technology that allows scientists to modify an organism’s DNA. This technique has the potential to treat genetic disorders, improve agricultural practices, and even eradicate certain diseases. The origins of gene editing trace back to the discovery of restriction enzymes in the 1970s. However, it was the advent of CRISPR-Cas9 in 2012 that truly propelled gene editing into a new era. This system, derived from bacteria, enables precise alterations to DNA, making gene editing more accessible and effective.
The potential applications of gene editing are vast. It offers hope for curing genetic diseases such as cystic fibrosis and sickle cell anemia. Additionally, it has the potential to advance cancer treatments, and even eradicate malaria by modifying mosquito DNA. In agriculture, gene editing can be used to create crops with desirable traits such as drought resistance or higher nutritional value.
Several companies are at the forefront of gene editing technology. CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics are among the pioneers, working on therapies for genetic disorders and other diseases. Moreover, companies like Monsanto and DuPont are exploring agricultural applications of gene editing.
Despite its potential, gene editing raises ethical and safety concerns. The possibility of “designer babies” and the long-term effects of genetic modifications are among the issues that spark debate. Moreover, the accessibility and affordability of gene editing therapies could exacerbate existing healthcare inequities.
Gene editing is a groundbreaking technology with the power to address many of humanity’s pressing challenges. As research advances and ethical discussions continue, the future of gene editing holds immense promise thanks to advancements in technology and a growing acceptance of gene therapies for treating a variety of diseases. Here’s a synthesis of forecasts and insights regarding the future of gene editing companies from multiple sources:
- Market Growth:
- The global gene editing market is expected to grow from $6.35 billion in 2022 to $7.44 billion in 2023, marking a compound annual growth rate (CAGR) of 17.3%.
- Further projections indicate that the gene editing market could reach $7.4 billion by 2031, with a segment showcasing a CAGR of 7.9% throughout the forecast period. Another source estimates the market to be valued at USD 36.4 Billion by 2032 with a CAGR of 18.1% from 2023 to 2032.
- The global CRISPR market is also poised for expansion, projected to reach USD 7.1 billion by 2028 from USD 3.4 billion in 2023, displaying an impressive CAGR as well.
- Gene Therapy Approvals:
- The Alliance for Regenerative Medicine predicts that 2023 could see at least five more gene therapies for rare diseases hitting the U.S. market, including potential new treatments for sickle cell disease, Duchenne muscular dystrophy, and hemophilia A.
- Company-Specific Forecasts:
- Editas Medicine: The company is expected to administer its EDIT-301 treatment in 20 sickle-cell patients by the year’s end, with the US FDA granting regenerative medicine advanced therapy designation to EDIT-301 to speed up the development and review process.
- CRISPR Therapeutics: This company, in collaboration with Vertex Pharmaceuticals, is working on a gene editing platform, exa-cel, for sickle cell disease. If approved, exa-cel is expected to treat both sickle cell and beta-thalassemia, an inherited blood disorder, presenting a “multibillion-dollar opportunity” in the future according to Vertex CEO Reshma Kewalrami.
- Investment Opportunities:
- A notable investment vehicle is the Global X Genomics and Biotechnology ETF (GNOM), which provides diversification with 41 gene editing-related stocks. Top holdings include CRISPR Therapeutics, Sarepta Therapeutics, Intellia Therapeutics, Beam Therapeutics, and Gilead Sciences, among others.
These forecasts and developments suggest a vibrant future for gene editing companies with significant market growth, new therapy approvals, and substantial investment opportunities. The continual advancement in gene editing technologies and a conducive regulatory environment will likely propel the sector forward, making it an intriguing area for both investors and stakeholders in the healthcare industry.
Let us know in a comment what you think about gene editing